Remove Demo Remove Drug Development Remove Trials
article thumbnail

The Trust Fall: Building Successful & Diverse Trials Outside the U.S.

H1 Blog

Breaking Down Barriers to International Clinical Trials Global Disruptions, Health Equity & Data Sharing As the U.S. A recent McKinsey analysis of drugs and vaccines developed since 2000 shows that it takes nearly ten years to go from clinical testing to approval. First let’s look at some challenges and then opportunities.

Trials 59
article thumbnail

FDA Poised to Make Impact on Underrepresented Populations in Clinical Studies

H1 Blog

Increasing diversity in clinical trials not only makes the findings more relevant to various patient groups, but also enhances knowledge about the disease or medical product being studied. This allows the trial to achieve more precise results at the indication level through leveraging comprehensive information from across the globe.

FDA 59
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Drug Approvals and Development Hinge on Diversity

H1 Blog

The success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within a trial population helps ensure the safety and efficacy of drugs that reach the market.

article thumbnail

Building an Exclusive Strategy with Inclusive HCPs

H1 Blog

In this blog post, we’ll explore how early diversity in HCP engagement can drive better outcomes and equity in drug development. The drug development process is known to be often expensive, lengthy, and full of trial and error before finding success.

article thumbnail

Optimizing Clinical Data Registries: Opportunities for Diversity and Feasibility

H1 Blog

Breaking the Barriers: How Inaccurate Trial Records Are Delaying Drug Development and Limiting Diverse Patient Populations In an October 2023 report , BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical trials.